Brokerages Expect Apellis Pharmaceuticals Inc (APLS) Will Post Earnings of -$0.72 Per Share

Wall Street analysts forecast that Apellis Pharmaceuticals Inc (NASDAQ:APLS) will report ($0.72) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Apellis Pharmaceuticals’ earnings. Apellis Pharmaceuticals reported earnings per share of ($0.43) in the same quarter last year, which indicates a negative year over year growth rate of 67.4%. The business is scheduled to issue its next quarterly earnings results on Monday, April 29th.

According to Zacks, analysts expect that Apellis Pharmaceuticals will report full year earnings of ($3.02) per share for the current financial year, with EPS estimates ranging from ($3.06) to ($2.97). For the next fiscal year, analysts expect that the company will report earnings of ($3.32) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Apellis Pharmaceuticals.

Several research firms have issued reports on APLS. Zacks Investment Research upgraded shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, March 4th. Citigroup boosted their price objective on shares of Apellis Pharmaceuticals from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, December 6th. Cantor Fitzgerald set a $53.00 target price on shares of Apellis Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 3rd. B. Riley initiated coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 8th. They issued a “buy” rating and a $40.00 target price for the company. Finally, JPMorgan Chase & Co. downgraded shares of Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $34.00 target price for the company. in a research note on Wednesday, January 23rd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Apellis Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $39.33.

APLS opened at $19.82 on Friday. The company has a quick ratio of 11.89, a current ratio of 11.89 and a debt-to-equity ratio of 0.16. Apellis Pharmaceuticals has a 52-week low of $11.45 and a 52-week high of $32.00. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -5.39 and a beta of 0.37.

In other news, major shareholder Morningside Venture Investment bought 441,176 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $7,499,992.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 9.30% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in APLS. Hillhouse Capital Advisors Ltd. purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at $29,410,000. BlackRock Inc. boosted its stake in shares of Apellis Pharmaceuticals by 30.8% in the fourth quarter. BlackRock Inc. now owns 3,730,626 shares of the company’s stock valued at $49,208,000 after purchasing an additional 877,431 shares during the period. Fiduciary Trust Co. purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at $9,306,000. Orbimed Advisors LLC acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $4,313,000. Finally, Fosun International Ltd acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $3,908,000. Institutional investors and hedge funds own 47.97% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Read More: Convertible Shares

Get a free copy of the Zacks research report on Apellis Pharmaceuticals (APLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.